Cyclosporin A-induced cell kill in vitro in various clinical-hematological types of B-cell chronic lymphocytic leukemia

Leukemia Research

Volumn 24, Issue 10, 2000, Pages 805-812

  Koski, Tomi ^a   Aine, Risto ^a   Vilpo, Leena ^a   Vilpo, Juhani ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Apoptosis; Chemotherapy; Chronic lymphocytic leukemia; Cyclosporin A; Cytotoxicity

Indexed keywords

CYCLOSPORIN A;

ADULT; AGED; APOPTOSIS; ARTICLE; CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; MALE; PRIORITY JOURNAL;

AGED; CELL DEATH; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED;

EID: 0033847981     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00050-3     Document Type: Article

References (25)

1. Nabel G. A transformed view of cyclosporine. Nature. 397:1999;471-472.
2. Diasio R, LoBuglio A. Immunomodulators: immunosuppressive agents and immunostimulants. In: Hardman J, Limbird L, Molinoff P, Ruddon R, Gilman A, Hardman J, Limbird L, Molinoff P, Ruddon R, Gilman As, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 9th ed. McGraw-Hill, 1995.
3. Chikkappa G., Pasquale D., Phillips P.G., Mangan K.F., Tsan M.F. Cyclosporin-A for the treatment of pure red cell aplasia in a patient with chronic lymphocytic leukemia. Am. J. Hematol. 26:1987;179-189.
4. Christen R., Morant R., Fehr J. Cyclosporin-A therapy of pure red cell aplasia in a patient with B-cell chronic lymphocytic leukemia. Eur. J. Haematol. 42:1989;303-307.
5. Garcia Vela J.A., Pontes M.J., Monteserin M.C., Ona F., Lastra A.M., Perez V., Gilsanz F. Pure red cell aplasia and cyclosporine. Am. J. Hematol. 49:1995;172-173.
6. Cesana C., Carlo-Stella C., Mangoni L., Almici C., Giachetti R., Zappa M., Rizzoli V. Response to cyclosporin A and recombinant human erythropoietin in a case of B cell chronic lymphocytic leukemia and pure red cell aplasia. Leukemia. 10:1996;1400-1401.
7. Emilia G., Messora C., Bensi L. The use of cyclosporin-A in the treatment of B-chronic lymphocytic leukemia. Leukemia. 9:1995;357-361.
8. Bergui L., Gregoretti M.G., Caligaris-Cappio F. Cyclosporin A in the treatment of B-chronic lymphocytic leukemia (B-CLL). Leukemia. 8:1994;1245-1246.
9. Eisterer W., Neyer U., Hilbe W., Diem G., Ohlschlegel C., Ludescher C., Thaler J. Effect of cyclosporin A in a patient with refractory nephrotic syndrome associated with B chronic lymphocytic leukemia. Nephron. 72:1996;468-471.
10. Grea M., Burgess R., Fisher A., Yin J. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia. Leuk. Res. 23:1999;29-35.
11. Larsson R., Jonsson B., Csoka K., Kristensen J., Nilsson K., Nygren P. Selective cytotoxic activity of cyclosporins against tumor cells from patients with B cell chronic lymphocytic leukemia. Eur. J. Pharmacol. 228:1992;237-240.
12. Maia R.C., Vasconcelos F.C., Harab R.C., Coelho A.M., Dobbin J.A., Rumjanek V.M. Comparison between anthracyclines and rhodamine-123 accumulation in chronic lymphoid leukemia: effect of cyclosporin A and verapamil. Tumour Biol. 19:1998;41-51.
13. Schmid M., Merk B., Porzsolt F. Cyclosporin A inhibits cytokine-induced proliferation in B-chronic lymphocytic leukemia. Leuk. Lymph. 15:1994;317-325.
14. Van Den Neste E., Maerevoet M., Martiat P., Ferrant A., Delannoy A., Michaux J.L. Cyclosporin A in the treatment of refractory B chronic lymphocytic leukemia (B-CLL). Leukemia. 9:1995;1102-1103.
15. Bennett J., Catovsky D., Daniel M.-T., Flandrin G., Galton D., Gralnick H., Sultan C. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J. Clin. Pathol. 42:1989;567-584.
16. Binet J., Auquier A., Digihiero G. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 48:1981;198-206.
17. General Haematologic Task Force of BCSH. Immunophenotyping in the diagnosis of chronic lymphoproliferative disorders. J Clin Pathol 1994;47:871-5.
18. Rozman C., Hernandez-Nieto L., Montserrat E., Brugues R. Prognostic significance of bone-marrow patterns in chronic lymphocytic leukaemia. Br. J. Haematol. 47:1981;529-537.
19. Matutes E., Catovsky D. The value of scoring systems for the diagnosis of biphenotypic leukemia and mature B-cell disorders. Leuk. Lymph. 13:1994;11-14.
20. Vilpo J., Vilpo L., Hulkkonen J., Lankinen M., Kuusela P., Hurme M. Non-specific binding compromises the purification yields of leukemic B-cells in chronic lymphocytic leukemia: prevention by collagen coating. Eur. J. Haematol. 60:1998;65-67.
21. Hulkkonen J., Vilpo J., Vilpo L., Hurme M. Diminished production of interleukin-6 in chronic lymphocytic leukaemia (B-CLL) cells from patients at advanced stages of disease. Br. J. Haematol. 100:1998;478-483.
22. Vilpo J., Vilpo L. Selective toxicity of vincristine against chronic lymphocytic leukaemia in vitro. The Tampere CLL Group. Lancet. 347:1996;1491-1492.
23. Koski T., Vilpo L., Vilpo J. Chemosensitivity in vitro to 2-chlorodeoxyadenosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in previously unexposed cases of chronic lymphocytic leukemia. Leuk. Res. 23:1999;277-279.
24. Russell R.G., Graveley R., Coxon F., Skjodt H., Del Pozo E., Elford P., Mackenzie A. Cyclosporin A. Mode of action and effects on bone and joint tissues. Scand. J. Rheumatol. Suppl. 95:1992;9-18.
25. Kipps T.J. Chronic lymphocytic leukemia. Curr. Opin. Hematol. 5:1998;244-253.